Enforcement Report - Week of July 24, 2024
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today positive topline results from its Phase 3 SPACE study evaluating the efficacy of AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years. The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. Safety data was consistent with that observed in adult populations, with no emergent safety signals. Full data from the SPACE study will be presented at a medical meeting later this year.
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
July 1 (Reuters) - The U.S. Federal Trade Commission has opened an investigation into Teva Pharmaceutical (TEVA.TA), opens new tab over the company's refusal to take down about two dozen patents for its asthma and COPD inhalers, the Washington Post reported on Monday, citing agency documents.
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Enforcement Report - Week of June 26, 2024
June 25 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday.
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
Teva launches generic version of Novo Nordisk`s diabetes drug Victoza
Teva sues Corcept over mifepristone `monopoly` for rare disorder